Abstract
Asthma is inadequately treated with the current standard of care. This session aimed to explore the potential of a phenotype-targeted approach to asthma management, which would allow a more tailored approach to treatment and result in better clinical outcomes for difficult-to-treat patients. Evidence was presented indicating that eosinophils play an important role in the pathogenesis of asthma. The importance of anti-interleukin (IL)-5 therapies, with the focus on therapies currently in development and their potential clinical benefit for the eosinophilic asthma phenotype, was also explored.
Reference29 articles.
1. 1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2015. Available at: http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf. Last accessed: 6 November 2015.
2. 2. Woodruff PG et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388-95.
3. 3. Hinks TS et al. Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms. J Allergy Clin Immunol. 2015;136(2):323-33.
4. 4. U-BIOPRED. U-BIOPRED Homepage. Available at: http://www.europeanlung.org/en/projects-and-research/projects/u-biopred/home. Last accessed: 6 November 2015.
5. 5. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Available at: https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf. Last accessed: 6 November 2015.